Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is a clinical-stage company developing artificial intelligence-driven epigenetic diagnostics for cardiovascular disease detection. The company entered the public markets in 2022 through a business combination with Mana Capital Acquisition Corp, a blank-check vehicle sponsored by Mana Capital LLC, and operates in the healthcare diagnostics sector. The S-1/A amendment filed January 13, 2023 reflects post-merger registration activity, a routine step in which SPAC-combined companies register shares for public resale following deal close. CDIO applies machine-learning and epigenomics technology to cardiac risk stratification. For comprehensive filing histories, deal timelines, and SPAC analytics on CDIO and thousands of other transactions, sign up for full data access on SpacDesk.